Xiangjun Qi

529 total citations
33 papers, 282 citations indexed

About

Xiangjun Qi is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Xiangjun Qi has authored 33 papers receiving a total of 282 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 10 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xiangjun Qi's work include Ferroptosis and cancer prognosis (6 papers), Traditional Chinese Medicine Studies (6 papers) and MicroRNA in disease regulation (4 papers). Xiangjun Qi is often cited by papers focused on Ferroptosis and cancer prognosis (6 papers), Traditional Chinese Medicine Studies (6 papers) and MicroRNA in disease regulation (4 papers). Xiangjun Qi collaborates with scholars based in China, Hong Kong and United States. Xiangjun Qi's co-authors include Guoming Chen, Zeyun Li, Xiaozhong Liao, Ruiting Lin, Tong Lin, Zhiqiang Chen, Lizhu Lin, Lingling Sun, Shujing Wang and Jie Jia and has published in prestigious journals such as Scientific Reports, Frontiers in Immunology and Medicine.

In The Last Decade

Xiangjun Qi

30 papers receiving 281 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiangjun Qi China 9 106 41 40 36 32 33 282
Jingru Ma China 10 154 1.5× 21 0.5× 41 1.0× 39 1.1× 25 0.8× 31 362
Haibo Zhang China 12 158 1.5× 31 0.8× 53 1.3× 55 1.5× 57 1.8× 19 317
Shumin Qin China 11 154 1.5× 37 0.9× 76 1.9× 42 1.2× 24 0.8× 25 345
Qingxian Huang China 10 95 0.9× 23 0.6× 68 1.7× 29 0.8× 33 1.0× 15 339
Yuxue Yang China 12 133 1.3× 26 0.6× 54 1.4× 75 2.1× 28 0.9× 23 341
Peiyu Xiong China 8 204 1.9× 80 2.0× 50 1.3× 35 1.0× 41 1.3× 21 343
Wafa Majeed Pakistan 8 93 0.9× 68 1.7× 23 0.6× 21 0.6× 40 1.3× 23 300
Krista D. Riche United States 7 155 1.5× 30 0.7× 52 1.3× 25 0.7× 20 0.6× 8 400

Countries citing papers authored by Xiangjun Qi

Since Specialization
Citations

This map shows the geographic impact of Xiangjun Qi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiangjun Qi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiangjun Qi more than expected).

Fields of papers citing papers by Xiangjun Qi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiangjun Qi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiangjun Qi. The network helps show where Xiangjun Qi may publish in the future.

Co-authorship network of co-authors of Xiangjun Qi

This figure shows the co-authorship network connecting the top 25 collaborators of Xiangjun Qi. A scholar is included among the top collaborators of Xiangjun Qi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiangjun Qi. Xiangjun Qi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Sun, Lingling, et al.. (2025). Anti-lung cancer therapy using nano-assembly particles of traditional Chinese Medicine formula. Materials Today Bio. 35. 102502–102502.
3.
Qi, Xiangjun, et al.. (2024). Vitamin E intake is inversely associated with NAFLD measured by liver ultrasound transient elastography. Scientific Reports. 14(1). 2592–2592. 16 indexed citations
4.
5.
6.
Chen, Zhiqiang, Lingling Sun, Xiangjun Qi, et al.. (2024). Yi-Fei-San-Jie Chinese medicine formula reverses immune escape by regulating deoxycholic acid metabolism to inhibit TGR5/STAT3/PD-L1 axis in lung cancer. Phytomedicine. 135. 156175–156175. 7 indexed citations
7.
Zhu, Yufei, et al.. (2024). Application of superb microvascular imaging technology in clinical disease activity of rheumatoid arthritis. Clinical Rheumatology. 43(11). 3293–3300. 1 indexed citations
8.
Qi, Xiangjun, et al.. (2023). The associations between dietary fibers intake and systemic immune and inflammatory biomarkers, a multi-cycle study of NHANES 2015–2020. Frontiers in Nutrition. 10. 1216445–1216445. 19 indexed citations
9.
Li, Yanlong, Caiyu Li, Xiangjun Qi, Ling Yu, & Lizhu Lin. (2023). Management of small cell lung cancer complicated with paraneoplastic Cushing’s syndrome: a systematic literature review. Frontiers in Endocrinology. 14. 1177125–1177125. 4 indexed citations
10.
Chen, Guo-Ming, Xiangjun Qi, Yang Luo, et al.. (2023). Characterization of cuproptosis in gastric cancer and relationship with clinical and drug reactions. Frontiers in Cell and Developmental Biology. 11. 1172895–1172895. 8 indexed citations
11.
Li, Zeyun, et al.. (2023). Multi-omics analysis reveals the prognostic and tumor micro-environmental value of lumican in multiple cancer types. Frontiers in Molecular Biosciences. 10. 1158747–1158747. 4 indexed citations
12.
Chen, Wen‐Ming, et al.. (2022). Comprehensive analysis of clinical prognosis and CLIC1 immune invasion in lung adenocarcinoma. Medicine. 101(39). e30760–e30760. 3 indexed citations
13.
Qi, Xiangjun, et al.. (2022). Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma. Journal of Immunology Research. 2022. 1–32. 4 indexed citations
14.
15.
Qi, Xiangjun, et al.. (2022). Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study. Frontiers in Pharmacology. 13. 921385–921385. 6 indexed citations
16.
Qi, Xiangjun, Xiaoqi Zhou, Lingling Sun, et al.. (2022). Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review. Heliyon. 8(9). e10581–e10581. 1 indexed citations
17.
Chen, Zhiqiang, Tong Lin, Xiaozhong Liao, et al.. (2021). Network pharmacology based research into the effect and mechanism of Yinchenhao Decoction against Cholangiocarcinoma. Chinese Medicine. 16(1). 13–13. 69 indexed citations
18.
Qi, Xiangjun, Xinrong Chen, Pei-Xin Li, et al.. (2021). Analysis of prescription regularity of traditional Chinese medicine for colorectal cancer based on data mining. China Journal of Chinese Materia Medica. 46(15). 4016–4022. 4 indexed citations
19.
Qi, Xiangjun, Guo-Ming Chen, Jing Li, et al.. (2021). Construction of a Novel Lung Adenocarcinoma Immune-Related lncRNA Pair Signature. International Journal of General Medicine. Volume 14. 4279–4289. 4 indexed citations
20.
Zhang, Li, et al.. (2018). Triiodothyronine Promotes Cell Proliferation of Breast Cancer via Modulating miR-204/Amphiregulin. Pathology & Oncology Research. 25(2). 653–658. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jingru Ma Breakdown of academic impact, for papers by Haibo Zhang Breakdown of academic impact, for papers by Shumin Qin Breakdown of academic impact, for papers by Qingxian Huang Breakdown of academic impact, for papers by Yuxue Yang Breakdown of academic impact, for papers by Peiyu Xiong Breakdown of academic impact, for papers by Wafa Majeed Breakdown of academic impact, for papers by Krista D. Riche
Rankless by CCL
2026